Los Angeles Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.2M | Sell |
88,278
-151,774
| -63% | -$51.6M | 0.12% | 154 |
|
|
2025
Q4 | $108M | Buy |
240,052
+80,658
| +51% | +$35.7M | 0.37% | 54 |
|
|
2025
Q3 | $72.7M | Buy |
159,394
+91,995
| +136% | +$37.5M | 0.25% | 78 |
|
|
2025
Q2 | $22M | Sell |
67,399
-13,463
| -17% | -$3.73M | 0.08% | 163 |
|
|
2025
Q1 | $21.8M | Sell |
80,862
-13,960
| -15% | -$3.59M | 0.1% | 156 |
|
|
2024
Q4 | $22.3M | Sell |
94,822
-42,195
| -31% | -$11.1M | 0.09% | 173 |
|
|
2024
Q3 | $37.7M | Buy |
137,017
+135,829
| +11,433% | +$35.4M | 0.15% | 124 |
|
|
2024
Q2 | $289K | Sell |
1,188
-1,771
| -60% | -$280K | ﹤0.01% | 1024 |
|
|
2024
Q1 | $442K | Sell |
2,959
-14,069
| -83% | -$2.35M | ﹤0.01% | 913 |
|
|
2023
Q4 | $3.26M | Buy |
+17,028
| New | +$2.9M | 0.01% | 388 |
|
|
2023
Q3 | – | Sell |
-1,507
| Closed | -$286K | – | 1111 |
|
|
2023
Q2 | $286K | Hold |
1,507
| – | – | ﹤0.01% | 1018 |
|
|
2023
Q1 | $302K | Sell |
1,507
-560
| -27% | -$118K | ﹤0.01% | 1003 |
|
|
2022
Q4 | $491K | Sell |
2,067
-4,045
| -66% | -$863K | ﹤0.01% | 910 |
|
|
2022
Q3 | $1.22M | Buy |
+6,112
| New | +$1.17M | 0.01% | 631 |
|
|
2019
Q4 | – | Sell |
-4,081
| Closed | -$328K | – | 1262 |
|
|
2019
Q3 | $328K | Sell |
4,081
-1,040
| -20% | -$82.3K | ﹤0.01% | 1102 |
|
|
2019
Q2 | $372K | Sell |
5,121
-44,324
| -90% | -$3.4M | ﹤0.01% | 1120 |
|
|
2019
Q1 | $4.62M | Sell |
49,445
-390
| -0.8% | -$32.6K | 0.03% | 447 |
|
|
2018
Q4 | $3.63M | Sell |
49,835
-97,268
| -66% | -$7.48M | 0.02% | 426 |
|
|
2018
Q3 | $12.9M | Sell |
147,103
-155,592
| -51% | -$15.7M | 0.07% | 302 |
|
|
2018
Q2 | $29.8M | Buy |
302,695
+232,782
| +333% | +$23.1M | 0.17% | 158 |
|
|
2018
Q1 | $8.33M | Buy |
+69,913
| New | +$9.01M | 0.05% | 349 |
|
|
2016
Q4 | – | Sell |
-161,415
| Closed | -$10.9M | – | 1156 |
|
|
2016
Q3 | $10.9M | Buy |
+161,415
| New | +$11.4M | 0.09% | 279 |
|
|
2016
Q1 | – | Sell |
-13,255
| Closed | -$1.25M | – | 1122 |
|
|
2015
Q4 | $1.25M | Sell |
13,255
-2,005
| -13% | -$186K | 0.01% | 617 |
|
|
2015
Q3 | $1.23M | Sell |
15,260
-5,972
| -28% | -$664K | 0.01% | 642 |
|
|
2015
Q2 | $2.54M | Sell |
21,232
-141,825
| -87% | -$16.9M | 0.02% | 519 |
|
|
2015
Q1 | $17M | Buy |
+163,057
| New | +$16.5M | 0.16% | 176 |
|
|
2014
Q2 | – | Sell |
-16,785
| Closed | -$1.13M | – | 1197 |
|
|
2014
Q1 | $1.13M | Buy |
+16,785
| New | +$1.3M | 0.01% | 640 |
|
|
2013
Q4 | – | Sell |
-3,955
| Closed | -$253K | – | 1269 |
|
|
2013
Q3 | $253K | Buy |
+3,955
| New | +$197K | ﹤0.01% | 1145 |
|
Other funds holding ALNY
VPM
VCM
Los Angeles Capital Management's ALNY Position: Q1 2026 in Review
Los Angeles Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 63% in Q1 2026, selling an estimated $51.6M and leaving 88,278 shares worth $29.2M. The position accounts for 0.12% of the portfolio, ranked #154.
Los Angeles Capital Management first reported a position in ALNY in Q3 2013 and has held it in 28 quarters since. The position peaked at $108M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Los Angeles Capital Management held 88,278 shares of Alnylam Pharmaceuticals worth $29.2M as of Q1 2026.
- Los Angeles Capital Management sold 151,774 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $51.6M.
- Alnylam Pharmaceuticals made up 0.12% of Los Angeles Capital Management's portfolio in Q1 2026, its #154 holding.
- Los Angeles Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 28 quarters since.
- Los Angeles Capital Management's Alnylam Pharmaceuticals position peaked at $108M in Q4 2025.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.